1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Bionet Corp.

Bionet Corp.

TTPEX:1784
54.10
TWD
-1.00
(-1.81%)
0.17EPS
59.82P/E
3.37BMarket Cap
Nov 17Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
12.69
11.36
11.29
12.32
12.63
14.04
14.65
15.25
17.42
18.65
22.36
24.13
24.51
25.62
Basic EPS, GAAP
0.96
0.8
0.42
-0.17
-0.11
0.44
0.13
0.24
0.5
0.72
1.55
1.65
1.02
1.13
Free Cash Flow per Basic Share
0.25
1.15
0.37
-0.64
-0.65
-0.54
-0.27
0.67
-0.05
1.17
2.52
1.44
0.31
1.27
Dividend per Share
1.04
0.92
0.63
0.37
- -
0.14
0.47
0.35
0.17
0.45
0.65
0.65
1.39
- -
Book Value per Share
21.26
21.15
20.89
20.43
20.26
20.61
20.21
20.3
20.65
20.69
22.56
26.26
25.29
24.65
Tangible Book Value per Share
21
20.89
20.65
20.15
20.01
20.37
19.88
19.54
19.91
20.02
21.94
25.7
24.67
24.06
Basic Weighted Avg Shares
55
55
55
55
55
55
53
53
53
53
50
51
50
51
Sales/Revenue/Turnover
694
624
622
679
697
771
776
807
921
980
1,127
1,222
1,237
1,294
Operating Margin (%)
0.63
-1
-0.26
-3.57
-0.41
4.43
1.14
-0.37
3.42
6.12
7.66
5.16
-0.98
-0.88
Depreciation Expense
39
31
31
30
29
28
42
38
39
43
40
46
62
74
Net Income, GAAP
52
44
23
-9
-6
24
7
13
27
38
78
84
51
57
Effective Tax Rate (%)
43.25
11.28
37.47
- -
- -
18.56
19.16
80.61
20.75
23.94
23.99
31.67
95.6
61.04
Profit Margin (%)
7.54
7.04
3.72
-1.39
-0.9
3.14
0.88
1.58
2.89
3.87
6.95
6.85
4.16
4.42
Working Capital
825
385
633
624
641
601
587
534
438
504
943
1,604
1,466
1,471
LT Debt
- -
- -
- -
- -
- -
- -
7
7
8
6
6
20
31
28
Total Equity
1,453
1,433
1,397
1,378
1,372
1,340
1,307
1,289
1,316
1,325
1,722
2,396
2,257
2,201
Return on Invested Capital (%)
0.17
-0.38
-0.07
- -
- -
2.03
0.49
-0.06
1.86
3.22
4.1
1.98
-0.03
-0.26
Return on Capital (%)
6.5
4.19
2.36
- -
- -
0.82
-0.5
1.84
1.58
1.7
4.87
4.62
4.2
4.6
Return on Common Equity (%)
4.51
3.76
2
-0.83
-0.56
2.18
0.63
1.19
2.45
3.49
6.91
6.64
3.95
4.59

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
85
102
113
LT Borrowings
- -
- -
- -
LT Finance Leases
31
29
28
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
50
50
50
Market Capitalization
5,207
3,808
3,371

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,871
1,933
1,921
Cash, Cash Equivalents & STI
1,401
1,468
1,463
Accounts Receivable, Net
265
262
266
Inventories
126
117
114
Total Current Liabilities
405
457
450
Payables & Accruals
- -
- -
- -
ST Debt
85
102
113
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.81%
13.22%
-5.78%
Free Cash Flow
-312.1%
-487.72%
-78.28%
Net Income, GAAP
-41.93%
45.25%
-38.56%
Sales/Revenue/Turnover
7.22%
9.04%
1.19%
Total Cash Common Dividend
- -
53.54%
111.33%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
296
293
304
329
1,222
2025
291
304
298
343
1,237
2026
315
338
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.44
0.33
0.23
0.65
1.65
2025
0.3
0.23
0.2
0.29
1.02
2026
0.25
0.39
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.65
2025
- -
- -
- -
- -
1.39
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Tien Lai Liu
Full Time Employees
80
Sector
Health technology
Industry
Biotechnology
Address
No.28, Xinhu 1st Road Taipei TP Taiwan 114065
IPO Date
Sep 17, 2004
Website
babybanks.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
BIONET Corp. (1784.TWO) provides cell therapy, regenerative medicine, and precision health services primarily in Taiwan and internationally across 17 countries. Founded in 1999 and headquartered at No. 28, Xinhu 1st Road, Taipei City, Taiwan, the company offers stem cell banking including hematopoietic stem cell storage from cord blood and adult peripheral blood; mesenchymal stem cell storage from umbilical cord tissue, adipose tissue, and dental pulp; immune cell banking and therapies featuring NK cells and CIK cells for cancers such as colorectal, lung, breast, and liver cancer; customized exosome services encompassing amniotic fluid exosomes, cord blood exosomes, platelet-rich exosomes, and mesenchymal stem cell-derived exosomes; genetic testing services; non-invasive prenatal chromosomal testing (NIPT); stem anti-aging and ANIKINE series products; and additional offerings in analytical testing, clinical and preclinical research, and commercialized cell-derived products. BIONET operates through key subsidiaries including GGA Corp. (4160.TWO), focused on genetic testing and digital health since 2008, and BIONET Therapeutics Corp. (7808.TWO), established in 2022 as a pioneer in AI-driven exosome technology and approved under Taiwan's biotechnology and pharmaceutical qualifications, with an emerging stock board listing in December 2024. The company serves over 1.8 million customers, including 50% of Taiwan's newborns and 95% of gynecology and reproductive centers, and partners with more than 500 medical institutions for over 850 stem cell transplants across 70+ diseases; it holds 63 Ministry of Health and Welfare-approved cell therapy projects, leading Taiwan with 80% of adipose-derived stem cell therapy enrollments. Recent developments encompass expansion of AI-exosome regenerative medicine collaborations with thousands of enterprises; BIONET Therapeutics' market debut leveraging scalable exosome foundry capabilities; and sustained growth in obstetrics, gynecology, and immunology applications including regulatory T cell therapies.